
OstarineBenefits, Dosage & Interactions
Also known as: MK-2866, Enobosarm
Ostarine, also known by its research code MK-2866 or Enobosarm, is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar effects to androgenic drugs but with reduced androgenic side effects. Research on Ostarine focuses on muscle and strength and bone and joint health.
How much Ostarine do people take?
1 mg and 3 mg daily arms in the phase 2 cancer-cachexia trial. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Ostarine — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
2 human randomized trials published.
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- 1 mg and 3 mg daily arms in the phase 2 cancer-cachexia trial[1]
- Route studied
- Oral[1]
- Frequency
- Once daily[1]
- Cycle length
- 16 weeks in the phase 2 trial[1]
- Half-life
- Roughly 24 hours, supporting once-daily dosing[1]
- Storage
- Room temperature, dry[1]
Reported for Ostarine in the cited sources. Published ranges are not dosing advice.
Ostarine compared with similar compounds
| Attribute | Ostarine (enobosarm) | Ligandrol (LGD-4033) | Testolone (RAD-140) | Cardarine (GW501516) |
|---|---|---|---|---|
| Class | Nonsteroidal SARM | Nonsteroidal SARM | Nonsteroidal SARM | PPAR-delta agonist (not a SARM) |
| Route | Oral | Oral | Oral | Oral |
| Half-life | ~24 hours | 24-36 hours | Not established in humans | Not established in humans |
| Evidence grade | Moderate | Limited | Preclinical | Preclinical |
| Oral stability | Orally active | Orally active | Orally active | Orally active |
| Typical published cycle | 12-16 weeks in the published phase 2 trials | 3 weeks in the only published healthy-volunteer trial | No published human dosing trial | No published human dosing trial |
| Main studied use | Muscle wasting in cancer (investigational) | Lean mass in healthy young men (phase 1) | Androgen receptor signaling (preclinical) | Endurance and lipid metabolism (animal work) |
References & evidence
Documents the Ostarine entry is written from. Each number matches an inline marker above.
- [1]Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialDobs AS, Boccia RV, Croot CC, et al. · The Lancet Oncology · 2013 · Peer-reviewed · PMID 23499390
- [2]The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young menBasaria S, Collins L, Dillon EL, et al. · The Journals of Gerontology: Series A · 2013 · Peer-reviewed · PMID 22459616
References & Evidence
Sources on this page that document Ostarine dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Ostarine studied for?
What is Ostarine?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
What does the research say about Ostarine?
Tap a section to expand.
Source for this section: Sources for How does Ostarine work?: Jumps to this entry in the sources and references list at the end of the page.
Source for this section: Sources for When should you take Ostarine?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Ostarine is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Ostarine?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Ostarine
Which studies looked at Ostarine?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia(opens PubMed in a new tab)Future Oncol · 2009 · PMID 19852734 · https://pubmed.ncbi.nlm.nih.gov/19852734/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 11326715(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/11326715
- WADA Prohibited List(opens in a new tab)World Anti-Doping Agency · wada-ama.org/en/prohibited-list
Verify at
Publisher search links for Ostarine. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Ostarine?
Plain-text summary, safe to quote verbatim:
Ostarine, also known by its research code MK-2866 or Enobosarm, is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar effects to androgenic drugs but with reduced androgenic side effects. Research on Ostarine focuses on muscle and strength and bone and joint health.
Ostarine cheat sheet
DoseRoutine cheat sheet · Hormone
Ostarine
Ostarine, also known by its research code MK-2866 or Enobosarm, is a selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar effects to androgenic drugs but with reduced androgenic side effects.
Evidence
Strong
2 human randomized trials published.
Studied range
1 mg and 3 mg daily arms in the phase 2 cancer-cachexia trial
Route
Oral
Frequency studied
Once daily
Half-life
Roughly 24 hours, supporting once-daily dosing
Storage
Room temperature, dry
Key references
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ostarine
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Ostarine — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ostarine
What compounds are similar to Ostarine?
Others in the hormone category or studied for the same goals.
Which goals is Ostarine used for?
Other compounds studied for the same benefits as Ostarine.
Continue exploring
See every compound DoseRoutine catalogs for these goals.
